A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Nov 5, 2018

Science Based Targets Initiative Approves Astellas’ Greenhouse Gas Reduction Plan

TOKYO, November 5, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that the company’s mid-to-long term greenhouse gas (GHG)...

Read more about Science Based Targets Initiative Approves Astellas’ Greenhouse Gas Reduction Plan
Oct 31, 2018

Astellas Announces Construction of New Research, Development and Manufacturing Facilities for Drugs Using Innovative Modalities/Technologies Including Antibodies and Cell Therapies

TOKYO, October 31, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that construction and renovation of new facilities for the...

Read more about Astellas Announces Construction of New Research, Development and Manufacturing Facilities for Drugs Using Innovative Modalities/Technologies Including Antibodies and Cell Therapies
Oct 30, 2018

ASN Kidney Week 2018: Data Presented from Two Japanese Phase 3 Studies on Roxadustat in the Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis

TOKYO and San Francisco, October 30, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Thomas B. Neff,...

Read more about ASN Kidney Week 2018: Data Presented from Two Japanese Phase 3 Studies on Roxadustat in the Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis
Oct 29, 2018

Astellas Receives European Approval for XTANDI™ (enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer

Results from the PROSPER trial show a median metastasis-free survival (MFS) of 36.6 months for enzalutamide plus androgen deprivation therapy (ADT) vs. 14.7 months for men who received placebo plus ADT

TOKYO, October 29, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that the European Commission (EC) has approved a new indication...

Read more about Astellas Receives European Approval for XTANDI™ (enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer
Oct 23, 2018

Astellas and BANDAI NAMCO Entertainment to Jointly Develop Smartphone Exercise Support App

TOKYO , October 23, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and BANDAI NAMCO Entertainment Inc. (President and CEO: Satoshi Oshita,...

Read more about Astellas and BANDAI NAMCO Entertainment to Jointly Develop Smartphone Exercise Support App
Oct 9, 2018

Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Announce Second Public Recruitment Offering of "JOINUS®", a Joint Research Program to Discover New Drugs using Drug-Repositioning Compound Library

TOKYO and OSAKA, October 9, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), Mitsubishi Tanabe Pharma Corporation (TSE: 4508, President and CEO:...

Read more about Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Announce Second Public Recruitment Offering of "JOINUS®", a Joint Research Program to Discover New Drugs using Drug-Repositioning Compound Library
Oct 5, 2018

CYTOKINETICS AND ASTELLAS PROVIDE UPDATES REGARDING COLLABORATIVE SKELETAL MUSCLE PROGRAM

SOUTH SAN FRANCISCO, Calif., and TOKYO, Oct. 5, 2018 – Cytokinetics, Incorporated (Nasdaq: CYTK, “Cytokinetics”) and Astellas Pharma Inc. (TSE: 4503, “Astellas”) today provided an update...

Read more about CYTOKINETICS AND ASTELLAS PROVIDE UPDATES REGARDING COLLABORATIVE SKELETAL MUSCLE PROGRAM
Oct 1, 2018

Astellas Submits New Drug Application in Japan of Roxadustat for The Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis

TOKYO and San Francisco, October 1, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Thomas B. Neff,...

Read more about Astellas Submits New Drug Application in Japan of Roxadustat for The Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis
Sep 25, 2018

BLINCYTO® FOR DRIP INFUSION 35μg APPROVED IN JAPAN FOR THE TREATMENT OF RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

THE FIRST-AND-ONLY BISPECIFIC CD19-DIRECTED CD3 T CELL ENGAGER (BiTE®) IMMUNOTHERAPY

Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; President and Representative Director: Steve Sugino, “Amgen Astellas”) and Astellas Pharma Inc. (Headquarters, Tokyo; President and CEO:...

Read more about BLINCYTO® FOR DRIP INFUSION 35μg APPROVED IN JAPAN FOR THE TREATMENT OF RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Sep 25, 2018

Astellas Receives Positive CHMP Opinion for XTANDI^TM (enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer

Results from the PROSPER trial show a median metastasis-free survival (MFS) of 36.6 months for enzalutamide plus androgen deprivation therapy (ADT) vs 14.7 months for men who received placebo plus ADT1

TOKYO and CHERTSEY, September 24, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that The Committee for Medicinal Products for...

Read more about Astellas Receives Positive CHMP Opinion for XTANDI^TM (enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts